

Elekta to enhance cancer treatment in Croatia through strategic acquisition

STOCKHOLM – Elekta (EKTA-B.ST) today announced the acquisition of assets from its distributor in Croatia, a strategic move that will strengthen Elekta's market position and enhance cancer treatment capabilities in the region.

Arnaud Delhay, Elekta's Executive Vice President, Region Europe, said: "Elekta's enhanced presence in Croatia will significantly improve service support for our customers, ensuring timely maintenance and upgrades and lead to more opportunities to deliver advanced radiation therapy solutions to other hospitals and clinics in the country. We expect this direct presence to positively impact patient care by providing access to the best cancer treatment technologies available."

With this agreement, Elekta will establish an office in Zagreb, acquire service engineers and hire additional employees, including a country manager, to support its operations in Croatia.

Croatia's National Cancer Plan highlights the importance of radiotherapy in cancer treatment and notes that the ratio of linear accelerators (linacs) per population is 3.5 units per million inhabitants, while the European average is 5.3 units per million inhabitants. In 2024, the Croatian Ministry of Health signed an order for a dozen Elekta linacs and four brachytherapy systems, which will address this shortage.

#

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com).